MedTrace Logo

The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance

NCT00440752 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2008-03-26

No results posted yet for this study

Summary

The newly introduced antimalarial drug artemether-lumefantrine is currently recommended as second line antimalarial in Sudan. Recurrent infection after treatment with this drug has been associated with selection of certain genes in the malaria parasite. However there is no information on this association in Sudan.This study is going to look into the genetics of resistance to artemether-lumefantrine.

Conditions

  • Falciparum Malaria
  • Antimalarials

Sponsors & Collaborators

  • London School of Hygiene and Tropical Medicine

    collaborator OTHER

  • World Health Organization

    collaborator OTHER

  • International Atomic Energy Agency

    collaborator OTHER_GOV

  • Tropical Medicine Research Institute

    lead OTHER

Principal Investigators

  • Colin Sutherland, PhD. · London School of Hygiene and Tropical Medicine

  • Badria B El-Sayed, PhD · Tropical Medicine Research Institute

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-10-31
Completion
2006-12-31

Countries

  • Sudan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00440752 on ClinicalTrials.gov